Creative Diagnostics recently launched Pseudotyped VSV-SARS-CoV-2 Spike for research uses. The Pseudotyped Luciferase/GFP VSV is designed as a control for Creative Diagnostics' Pseudotyped Luciferase/GFP rSARS-CoV-2 Spike to test for non-specific factors that affect virus infectivity. Pseudotyped VSV-SARS-CoV-2 S-ΔG encodes the antigenomic-sense (or positive-sense) RNA of a replicaton-restricted recombinant vesicular stomatitis virus (rVSV) in which the glycoprotein (G) gene has been replaced with SARS-CoV-2 spike protein. The pseudotype VSV particles encode reporter gene (mCherry/GFP/Luciferase) together with the VSV nucleocapsid (N), phosphoprotein (P), and large polymerase subunit (L) in their pVSV-ΔG vector. When the VSV pseudovirus infect the target cells, reporter gene expression is proportional to the number of cells that were infected. VSV Envelope The Pseudovirus display the VSV envelope glycoprotein (VSV-G) pseudotyped on replication-incompetent virus particles that contain a heterologous lentiviral (HIV) core. The VSV-G protein confers the pseudovirus with a high level of single cycle infectivity due to its broad tropism. In the product release, various products are included, such as Pseudotyped VSV-SARS-CoV-2 S-ΔG-mCherry (COV-PSV10), Pseudotyped VSV-SARS-CoV-2 S-ΔG-EGFP (COV-PSV11), Pseudotyped VSV-SARS-CoV-2 S-ΔG-Luciferase (COV-PSV12), Pseudotyped Luciferase VSV (VSV-PS01), and Pseudotyped GFP VSV (VSV-PS02). For example, the Pseudotyped Luciferase VSV (VSV-PS01), which is designed as a control for Creative Diagnostics' Pseudotyped Luciferase rSARS-CoV-2 Spike to test for non-specific factors that affect virus infectivity. The Pseudovirus display the VSV envelope glycoprotein (VSV-G) pseudotyped on replication-incompetent virus particles that contain a heterologous lentiviral (HIV) core. Pseudovirus is capable of a single round of infection and carries a genome that expresses luciferase optical reporter gene upon infection. VSV Pseudovirus is produced in HEK-293T cells using three separate plasmids, encoding VSV-G, a lentiviral gag polyprotein, and a reporter gene. VSV Pseudovirus is created using a second-generation lentiviral system with components that are highly unlikely to recombine to produce a fully infectious virus (requiring 3 separate recombination events to do so). Another example is Pseudotyped VSV-SARS-CoV-2 S-ΔG-mCherry (COV-PSV10). It is a replication-restricted, recombinant pseudotyped VSV particle containing SARS-CoV-2 spike protein. Because the infectivity of Pseudotyped VSV-SARS-CoV-2 S-ΔG-mCherry is restricted to a single round of replication, the pseudotypes can be handled using BSL-2 containment practices. The pseudotype VSV particles encode mCherry in their pVSV-ΔG vector. When the VSV pseudotypes infect the target cells, mCherry expression is proportional to the number of cells that were infected. "COVID-19 is still threatening to our life and work. We are working to empower our scientific clients to fight against the pandemic by offering SARS-CoV-2 related products and services, such as SARS-CoV Antigens and Antibodies, Lentiviral SARS-CoV-2 Pseudovirus, SARS-CoV-2 Rapid Test Kit, SARS-CoV-2 Spike Stable Cell Line, SARS-CoV-2 Neutralizing Antibodies, and SARS-CoV-2 Pseudovirus Neutralization Assay. To help meet growing customer demand, we'll continue to provide research tools and assistance in their studies." said Dr. Jessica Waldorf, chief scientific officer of R&D department of Creative Diagnostics. If you can't a find a suitable pseudovirus or want to know more details of Pseudotyped VSV-SARS-CoV-2 Spike or other research materials, please visit Creative Diagnostics. About Creative Diagnostics Creative Diagnostics is a leading manufacturer and supplier of antibodies, viral antigens, innovative diagnostic components and critical assay reagents. It also provides contract biologic R&D and manufacturing services to the diagnostic manufacturers along with GMP biologics manufacturing for the biopharmaceutical market. It aims to provide a trusted source for all researchers' assay development and manufacturing needs.

SARS-CoV-2pseudotypeCreative Diagnostics